Meet Our Talented and Dedicated Team
At Telescope Therapeutics we are revolutionizing preclinical drug development by harnessing the power of patient-derived inducible pluripotent stem cells (iPSCs) and advanced biosensor technologies. Our mission is to transform how diseases are modelled, therapies are discovered, and drug efficacy is predicted, accelerating the journey from the lab to the patient.
Our Team
Our multidisciplinary team of scientists and professionals is dedicated to pushing the boundaries of preclinical research. With expertise in stem cell biology, pharmacology, bioengineering, and computational modeling, we collaborate to develop innovative solutions that address the complexities of human diseases.
Myriam Lavoie is a global biotechnology executive with over two decades of experience driving strategy, commercial execution, and corporate growth. As Chief Executive Officer of Telescope Therapeutics, she brings a commercial mindset and extensive product launch expertise to complement the company's scientific foundation. Having spent the majority of her career in the Boston biotechnology hub, she has a proven track record of building and leading highly productive teams at Biogen and Astria Therapeutics. Her leadership spans the entire product life cycle, from development strategy through the successful launch of multiple therapies and loss of exclusivity (LOE) management across biologics, small molecules, and ASO therapies.
As the Chief Scientific Officer of Telescope Therapeutics and a Professor in the Department of Pharmacology and Therapeutics at McGill University, Terry has a long-standing track record in the identification of molecular mechanisms involved in the function of GPCRs publishing more than 200 scientific papers. His work centers on novel signaling complexes and pathways associated with subcellular localization of G protein-coupled receptors (GPCRs) and G proteins, with a recent focus on using biosensors in iPSC-based models of disease for drug discovery. Fun Fact: he loves to play the harmonica and sing “House of the Rising Sun”.
As a Scientist at Telescope Therapeutics Ben leverages his master's degree in cancer mechanisms and organoid modeling in establishing iPSC models. His passion for this field of research stems from its fascinating potential to personalize medicine and run “clinical trials in a dish”. An avid reader, Ben can be found buried in an adventure novel, at the gym, or biking around Montréal.
Jiajia is contributing to the establishment and operation of our drug screening platform. She holds a degree in Veterinary Medicine from Zhejiang University, China, and recently completed her Master's in Biotechnology at McGill University. Her research background spans from animal disease models to GPCR related drug screening. Outside of the lab, Jiajia is a dedicated guqin (an ancient Chinese string instrument) player and enjoys painting.
Rasha is a PhD student at McGill University in Dr. Terry Hébert’s lab. During her internship with Telescope Therapeutics, she contributes to projects involving iPSC-derived models, building on the expertise she developed during her Master’s research in iPSC and organoid-based disease modeling. Her background in stem cell biology and patient-specific disease models allows her to support the development and characterization of iPSC-derived models at Telescope.
Tegvir is a fifth-year PhD candidate in Experimental Medicine at McGill University, where he studies GPCR signaling and functional selectivity in Dr. Stéphane Laporte’s laboratory at the RI-MUHC. As a doctoral intern at Telescope Therapeutics, he applies his expertise in GPCR pharmacology, assay development, mutagenesis, and cell-based screening to support the development of therapeutics targeting the urotensin receptor. Outside the lab, Tegvir enjoys reading, watching films, rock climbing, cycling, running, and discovering new cafés in his hometown of Montréal.
Our multidisciplinary team of scientists and professionals is dedicated to pushing the boundaries of preclinical research. With expertise in stem cell biology, pharmacology, bioengineering, and computational modeling, we collaborate to develop innovative solutions that address the complexities of human diseases.
Myriam Lavoie is a global biotechnology executive with over two decades of experience driving strategy, commercial execution, and corporate growth. As Chief Executive Officer of Telescope Therapeutics, she brings a commercial mindset and extensive product launch expertise to complement the company's scientific foundation. Having spent the majority of her career in the Boston biotechnology hub, she has a proven track record of building and leading highly productive teams at Biogen and Astria Therapeutics. Her leadership spans the entire product life cycle, from development strategy through the successful launch of multiple therapies and loss of exclusivity (LOE) management across biologics, small molecules, and ASO therapies.
As the Chief Scientific Officer of Telescope Therapeutics and a Professor in the Department of Pharmacology and Therapeutics at McGill University, Terry has a long-standing track record in the identification of molecular mechanisms involved in the function of GPCRs publishing more than 200 scientific papers. His work centers on novel signaling complexes and pathways associated with subcellular localization of G protein-coupled receptors (GPCRs) and G proteins, with a recent focus on using biosensors in iPSC-based models of disease for drug discovery. Fun Fact: he loves to play the harmonica and sing “House of the Rising Sun”.
As a Scientist at Telescope Therapeutics Ben leverages his master's degree in cancer mechanisms and organoid modeling in establishing iPSC models. His passion for this field of research stems from its fascinating potential to personalize medicine and run “clinical trials in a dish”. An avid reader, Ben can be found buried in an adventure novel, at the gym, or biking around Montréal.
Jiajia is contributing to the establishment and operation of our drug screening platform. She holds a degree in Veterinary Medicine from Zhejiang University, China, and recently completed her Master's in Biotechnology at McGill University. Her research background spans from animal disease models to GPCR related drug screening. Outside of the lab, Jiajia is a dedicated guqin (an ancient Chinese string instrument) player and enjoys painting.
Rasha is a PhD student at McGill University in Dr. Terry Hébert’s lab. During her internship with Telescope Therapeutics, she contributes to projects involving iPSC-derived models, building on the expertise she developed during her Master’s research in iPSC and organoid-based disease modeling. Her background in stem cell biology and patient-specific disease models allows her to support the development and characterization of iPSC-derived models at Telescope.
Tegvir is a fifth-year PhD candidate in Experimental Medicine at McGill University, where he studies GPCR signaling and functional selectivity in Dr. Stéphane Laporte’s laboratory at the RI-MUHC. As a doctoral intern at Telescope Therapeutics, he applies his expertise in GPCR pharmacology, assay development, mutagenesis, and cell-based screening to support the development of therapeutics targeting the urotensin receptor. Outside the lab, Tegvir enjoys reading, watching films, rock climbing, cycling, running, and discovering new cafés in his hometown of Montréal.
Our multidisciplinary team of scientists and professionals is dedicated to pushing the boundaries of preclinical research. With expertise in stem cell biology, pharmacology, bioengineering, and computational modeling, we collaborate to develop innovative solutions that address the complexities of human diseases.
Myriam Lavoie is a global biotechnology executive with over two decades of experience driving strategy, commercial execution, and corporate growth. As Chief Executive Officer of Telescope Therapeutics, she brings a commercial mindset and extensive product launch expertise to complement the company's scientific foundation. Having spent the majority of her career in the Boston biotechnology hub, she has a proven track record of building and leading highly productive teams at Biogen and Astria Therapeutics. Her leadership spans the entire product life cycle, from development strategy through the successful launch of multiple therapies and loss of exclusivity (LOE) management across biologics, small molecules, and ASO therapies.
As the Chief Scientific Officer of Telescope Therapeutics and a Professor in the Department of Pharmacology and Therapeutics at McGill University, Terry has a long-standing track record in the identification of molecular mechanisms involved in the function of GPCRs publishing more than 200 scientific papers. His work centers on novel signaling complexes and pathways associated with subcellular localization of G protein-coupled receptors (GPCRs) and G proteins, with a recent focus on using biosensors in iPSC-based models of disease for drug discovery. Fun Fact: he loves to play the harmonica and sing “House of the Rising Sun”.
As a Scientist at Telescope Therapeutics Ben leverages his master's degree in cancer mechanisms and organoid modeling in establishing iPSC models. His passion for this field of research stems from its fascinating potential to personalize medicine and run “clinical trials in a dish”. An avid reader, Ben can be found buried in an adventure novel, at the gym, or biking around Montréal.
Jiajia is contributing to the establishment and operation of our drug screening platform. She holds a degree in Veterinary Medicine from Zhejiang University, China, and recently completed her Master's in Biotechnology at McGill University. Her research background spans from animal disease models to GPCR related drug screening. Outside of the lab, Jiajia is a dedicated guqin (an ancient Chinese string instrument) player and enjoys painting.
Rasha is a PhD student at McGill University in Dr. Terry Hébert’s lab. During her internship with Telescope Therapeutics, she contributes to projects involving iPSC-derived models, building on the expertise she developed during her Master’s research in iPSC and organoid-based disease modeling. Her background in stem cell biology and patient-specific disease models allows her to support the development and characterization of iPSC-derived models at Telescope.
Tegvir is a fifth-year PhD candidate in Experimental Medicine at McGill University, where he studies GPCR signaling and functional selectivity in Dr. Stéphane Laporte’s laboratory at the RI-MUHC. As a doctoral intern at Telescope Therapeutics, he applies his expertise in GPCR pharmacology, assay development, mutagenesis, and cell-based screening to support the development of therapeutics targeting the urotensin receptor. Outside the lab, Tegvir enjoys reading, watching films, rock climbing, cycling, running, and discovering new cafés in his hometown of Montréal.
Co-founders
Collaborators and Incubators
